Study Review – Rivaroxaban vs enoxaparin/vitamin K antagonist in VTE

As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study titled: Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.

Independent expert commentary is provided by Dr Scott Dunkley, a senior staff specialist haematologist at Royal Prince Alfred Hospital, Sydney and the Thrombosis and Pregnancy Clinic at Charles Perkins Centre, University of Sydney.

* Revised Copy September 2022
 

Please login below to download this issue (PDF)

Subscribe